Drug Profile
Human albumin/von Willebrand factor - ViRexx
Alternative Names: Occlusin 50 InjectionLatest Information Update: 04 Feb 2014
Price :
$50
*
At a glance
- Originator ViRexx Medical Corp
- Class Antineoplastics; Blood coagulation factors; Coagulants; Plasma expanders
- Mechanism of Action Platelet activating factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 04 Feb 2014 Discontinued - Phase-I for Liver cancer in Canada (Intrahepatic)
- 31 Dec 2008 No development reported - Phase-I for Liver cancer in Canada (Intrahepatic)
- 23 Dec 2008 ViRexx Medical Corp has been acquired and merged into Paladin Labs